All In Biotech

Free tool

FAERS Monitor: Redemplo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219947 or its brand name (Redemplo, Plozasiran Sodium). Reports on generic versions are filed under their own applications.

Reports

104

Serious

13

13% of reports

Hospitalization

11

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache21
  • nausea20
  • blood glucose increased15
  • injection site pain7
  • fatigue5
  • feeling abnormal5
  • hyperglycaemia5
  • blood triglycerides increased4
  • dizziness4
  • drug ineffective4
  • dyspnoea4
  • abdominal discomfort3
  • alanine aminotransferase increased3
  • back pain3
  • injection site bruising3

Reports by year received

View as table
YearReports
2026104

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,055 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood triglycerides increasedSignal445.817.5133
hyperglycaemiaSignal527.811.8104
blood glucose increasedSignal1516.110.1199
alanine aminotransferase increasedSignal39.93.216
injection site bruisingSignal37.62.511
headacheSignal216.84.6101
nauseaSignal205.13.465
injection site painSignal74.62.317
feeling abnormalSignal54.21.89
abdominal discomfort33.61.23
back pain32.60.92
dizziness41.60.60
dyspnoea41.40.50
fatigue51.30.60
drug ineffective40.60.21

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.